WO2024136604A1 - Souche de bifidobacterium breve et composition pour augmenter le nad+ et le nad total la comprenant - Google Patents
Souche de bifidobacterium breve et composition pour augmenter le nad+ et le nad total la comprenant Download PDFInfo
- Publication number
- WO2024136604A1 WO2024136604A1 PCT/KR2023/021477 KR2023021477W WO2024136604A1 WO 2024136604 A1 WO2024136604 A1 WO 2024136604A1 KR 2023021477 W KR2023021477 W KR 2023021477W WO 2024136604 A1 WO2024136604 A1 WO 2024136604A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nad
- bifidobacterium breve
- culture
- strain
- present
- Prior art date
Links
- 241000186012 Bifidobacterium breve Species 0.000 title claims abstract description 117
- 239000000203 mixture Substances 0.000 title claims abstract description 98
- 230000001965 increasing effect Effects 0.000 title description 23
- 210000003205 muscle Anatomy 0.000 claims abstract description 39
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 9
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims description 153
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims description 143
- 229950006238 nadide Drugs 0.000 claims description 143
- 235000013305 food Nutrition 0.000 claims description 56
- 235000020956 nicotinamide riboside Nutrition 0.000 claims description 52
- 239000011618 nicotinamide riboside Substances 0.000 claims description 52
- JLEBZPBDRKPWTD-TURQNECASA-O N-ribosylnicotinamide Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 JLEBZPBDRKPWTD-TURQNECASA-O 0.000 claims description 51
- 239000008194 pharmaceutical composition Substances 0.000 claims description 35
- 230000032683 aging Effects 0.000 claims description 33
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 230000002708 enhancing effect Effects 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 19
- 235000013376 functional food Nutrition 0.000 claims description 17
- 208000029578 Muscle disease Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 13
- 238000005728 strengthening Methods 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 10
- 239000006041 probiotic Substances 0.000 claims description 9
- 235000018291 probiotics Nutrition 0.000 claims description 9
- 208000001076 sarcopenia Diseases 0.000 claims description 9
- 230000002265 prevention Effects 0.000 claims description 7
- 230000000529 probiotic effect Effects 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 206010028289 Muscle atrophy Diseases 0.000 claims description 5
- 201000006938 muscular dystrophy Diseases 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 20
- 238000001727 in vivo Methods 0.000 abstract description 3
- 102000000344 Sirtuin 1 Human genes 0.000 abstract 1
- 108010041191 Sirtuin 1 Proteins 0.000 abstract 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 52
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 36
- 235000005152 nicotinamide Nutrition 0.000 description 26
- 239000011570 nicotinamide Substances 0.000 description 26
- 229960003966 nicotinamide Drugs 0.000 description 26
- 235000001968 nicotinic acid Nutrition 0.000 description 18
- 229960003512 nicotinic acid Drugs 0.000 description 18
- 239000011664 nicotinic acid Substances 0.000 description 18
- 230000037361 pathway Effects 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 13
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 11
- 108010064862 Nicotinamide phosphoribosyltransferase Proteins 0.000 description 11
- 102000015532 Nicotinamide phosphoribosyltransferase Human genes 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000003833 cell viability Effects 0.000 description 11
- 238000012048 forced swim test Methods 0.000 description 11
- 230000003387 muscular Effects 0.000 description 10
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 230000003834 intracellular effect Effects 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000002438 mitochondrial effect Effects 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 235000013355 food flavoring agent Nutrition 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010012289 Dementia Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101000588298 Homo sapiens Endoplasmic reticulum membrane sensor NFE2L1 Proteins 0.000 description 5
- 101000577547 Homo sapiens Nuclear respiratory factor 1 Proteins 0.000 description 5
- 108010024137 Nicotinamide-Nucleotide Adenylyltransferase Proteins 0.000 description 5
- 102000015597 Nicotinamide-nucleotide adenylyltransferase Human genes 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102100028744 Nuclear respiratory factor 1 Human genes 0.000 description 4
- 102000011990 Sirtuin Human genes 0.000 description 4
- 108050002485 Sirtuin Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000013334 alcoholic beverage Nutrition 0.000 description 3
- 230000001851 biosynthetic effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- -1 dried matter Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- JOUIQRNQJGXQDC-AXTSPUMRSA-N namn Chemical compound O1[C@@H](COP(O)([O-])=O)[C@H](O)[C@@H](O)[C@@H]1[N+]1=CC=CC(C(O)=O)=C1 JOUIQRNQJGXQDC-AXTSPUMRSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000005783 single-strand break Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 231100000582 ATP assay Toxicity 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000023105 Huntington disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102000000780 Nicotinate phosphoribosyltransferase Human genes 0.000 description 2
- 108700040046 Nicotinate phosphoribosyltransferases Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 238000003149 assay kit Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- SENPVEZBRZQVST-HISDBWNOSA-N deamido-NAD zwitterion Chemical compound [N+]1([C@@H]2O[C@@H]([C@H]([C@H]2O)O)COP([O-])(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@@H]([C@@H]2O)O)N2C=3N=CN=C(C=3N=C2)N)=CC=CC(C(O)=O)=C1 SENPVEZBRZQVST-HISDBWNOSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000011536 extraction buffer Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000015654 memory Effects 0.000 description 2
- 230000008437 mitochondrial biogenesis Effects 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YABIFCKURFRPPO-IVOJBTPCSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyridin-1-ium-3-carboxamide;chloride Chemical compound [Cl-].NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=C1 YABIFCKURFRPPO-IVOJBTPCSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FMGYKKMPNATWHP-UHFFFAOYSA-N Cyperquat Chemical compound C1=C[N+](C)=CC=C1C1=CC=CC=C1 FMGYKKMPNATWHP-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000001613 Gambling Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 1
- 101000685982 Homo sapiens NAD(+) hydrolase SARM1 Proteins 0.000 description 1
- 101000996052 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Proteins 0.000 description 1
- 101000996058 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 Proteins 0.000 description 1
- 101000996006 Homo sapiens Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3 Proteins 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 244000147568 Laurus nobilis Species 0.000 description 1
- 235000017858 Laurus nobilis Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100023356 NAD(+) hydrolase SARM1 Human genes 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100034451 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 1 Human genes 0.000 description 1
- 102100034450 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 2 Human genes 0.000 description 1
- 102100034456 Nicotinamide/nicotinic acid mononucleotide adenylyltransferase 3 Human genes 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229940078753 Sirtuin inhibitor Drugs 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 235000005212 Terminalia tomentosa Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000020299 breve Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002802 cardiorespiratory effect Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000006571 energy metabolism pathway Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 125000000627 niacin group Chemical group 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001308 poly(aminoacid) Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 239000010948 rhodium Substances 0.000 description 1
- 229910052703 rhodium Inorganic materials 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000013707 sensory perception of sound Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Definitions
- the present invention relates to a novel Bifidobacterium breve strain culture and a composition containing the same for enhancing NAD + and total NAD (nicotinamide adenine dinucleotide) in the body.
- NAD + and total NAD nicotinamide adenine dinucleotide
- the newly isolated Bifidobacterium breve strain It relates to a culture thereof and a pharmaceutical composition or food composition containing the same that can increase the level of NAD + total NAD in the body.
- the aging process reduces various physiological functions such as motor function, vision, hearing, immunity, and cognitive function. Aging can cause age-related diseases such as diabetes, cancer, and dementia. In order to delay the aging process, there is a need to treat diseases caused by aging.
- aging is a very complex phenomenon and involves various genetic and environmental factors, and nutrition and metabolism become important factors closely related to the aging process ⁇ Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell. (2013) 153:1194-217. ⁇
- NAD + (nicotinamide adenine dinucleotide) has attracted much attention as an anti-aging molecule.
- NAD + mediates various redox reactions in energy metabolism pathways such as glycolysis, tricarboxylic acid cycle, fatty acid oxidation, and mitochondrial phosphorylation.
- NAD + also functions as a substrate for PARP (poly(ADP-ribose) polymerase), sirtuin, CD38, and SARM1.
- PARP accumulates at DNA single strand break (SSB) sites and induces auto-ADP-ribosylation, which initiates the SSB repair process.
- SSB DNA single strand break
- Sirtuins are NAD + -dependent deacetylases/deacylases that regulate gene expression, stress response, and metabolism by removing acetyl/acyl groups from target protein lysine residues. NAD + mediates various aging processes through these functions.
- NAD + supplementation therapy is one way to slow the accelerated aging process by inhibiting the age-related decline of NAD + .
- NAMN L-tryptophan
- NAM nicotinic acid
- NAM NAMN
- NAM nicotinic acid
- NAM NAMN
- NAM nicotinamide
- NAMPT nicotinamide phosphoribosyltransferase
- NAM is the actual source of NAD + synthesis, but NAMPT is the rate-limiting enzyme.
- the production of NAD + from NAM is an inefficient reaction, and NAM is a sirtuin inhibitor and can cancel sirtuin-mediated beneficial effects.
- the Preiss-Handler pathway uses nicotinic acid (NA nicotinic acid) and the enzyme nicotinic acid phosphoribosyltransferase (NAPRT) to generate NAMN, which then converts NAMN to nicotinic acid adenine dinucleotide (NAAD) by the nicotinamide mononucleotide adenylyltransferases (NMNAT1, NMNAT2, and NMNAT3).
- NAAD nicotinamide mononucleotide adenylyltransferases
- Nicotinamide riboside (NR) and NMN are recognized as favorable NAD + precursors for NAD + replacement therapy.
- NR is a derivative of vitamin B3 (nicotinic acid), and many studies have shown that nicotinamide riboside enhances the metabolism of organisms, prevents aging of stem cells, and maintains the function of stem cells. (Katsyuba E, Romani M, Hofer D, Auwerx J. NAD homeostasis in health and disease. Nat Metab. (2020)).
- NMN is another NAD + precursor found in broccoli and others. Oral administration of NMN shows beneficial effects on diet- and aging-induced obesity and diabetes. Therefore, it has been shown that NMN feeding can improve age-related physiological decline in mice of various ages (Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab (2011) 14:528-36.
- the inventors of the present application isolated a novel Bifidobacterium strain that can delay aging or improve exercise ability by increasing the level of NAD + in the body and total NAD containing it, and confirmed its effect. , completed the present invention.
- the purpose of the present invention is to recognize the need for the present invention in the aforementioned prior art and to provide a new Bifidobacterium breve strain.
- the object of the present invention is to provide a culture of Bifidobacterium breve strain.
- the object of the present invention is to provide a composition capable of increasing NAD + levels in the body.
- the object of the present invention is to provide a composition for use in combination with nicotinamide riboside.
- the object of the present invention is to provide a composition for improving exercise performance or muscle endurance.
- An object of the present invention is to provide a composition for preventing, treating or improving muscle diseases.
- An object of the present invention is to provide a composition for strengthening muscles.
- An object of the present invention is to provide a composition for preventing, treating or improving aging-related diseases.
- the present invention provides Bifidobacterium breve ID-A11 strain or a culture thereof with accession number KCTC 15219BP.
- the present invention also provides a probiotic preparation containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition, food composition, or cosmetic composition containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition for increasing NAD + (nicotinamide adenine dinucleotide) and/or total NAD levels in the body, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof.
- NAD + nicotinamide adenine dinucleotide
- the present invention also includes the Bifidobacterium breve ID-A11 strain or a culture thereof, and provides NAD + (nicotinamide adenine dinucleotide) and/or in vivo for use in combination with nicotinamide riboside.
- NAD + nicotinamide adenine dinucleotide
- a pharmaceutical composition for enhancing total NAD is provided.
- the present invention also provides a pharmaceutical composition for enhancing exercise performance or muscular endurance containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition for enhancing exercise performance or muscular endurance, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. provides.
- the present invention also provides a pharmaceutical composition for preventing or treating muscle diseases containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition for preventing or treating muscle disease, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. to provide.
- the present invention also provides a pharmaceutical composition for muscle strengthening containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition for muscle strengthening, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside.
- the present invention also provides a pharmaceutical composition for preventing or treating aging-related diseases, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a pharmaceutical composition for the prevention or treatment of age-related diseases, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. provides.
- the present invention also provides a food composition for enhancing NAD + and/or total NAD levels in the body, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also includes the Bifidobacterium breve ID-A11 strain or a culture thereof, and promotes NAD + and/or total NAD levels in the body for use in combination with Nicotinamide Riboside. Provides a food composition for use.
- the present invention also provides a food composition for enhancing exercise performance or muscular endurance containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a food composition for enhancing exercise performance or muscular endurance, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. provides.
- the present invention also provides a food composition for preventing or improving muscle disease containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a food composition for preventing or improving muscle disease, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. to provide.
- the present invention also provides a food composition for muscle strengthening containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a food composition for muscle strengthening, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside.
- the present invention also provides a food composition for preventing or improving aging-related diseases containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a food composition for preventing or improving aging-related diseases, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. provides.
- the present invention also provides a food composition for preventing or improving aging containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides a food composition for preventing or improving aging, comprising the Bifidobacterium breve ID-A11 strain or a culture thereof, and for use in combination with nicotinamide riboside. do.
- the present invention also provides an anti-aging composition containing the Bifidobacterium breve ID-A11 strain or a culture thereof.
- the present invention also provides an anti-aging composition
- an anti-aging composition comprising the Bifidobacterium breve ID-A11 strain or a culture thereof and for use in combination with nicotinamide riboside.
- Figure 1 shows the NAD + synthesis pathway by Preiss-Handler and salvage pathways.
- FIG. 2 shows results showing that Bifidobacterium breve ID-A11 (KCTC 15219BP) according to the present invention affects the improvement of cell viability.
- Figure 3 compares Bifidobacterium breve ID-A11 and Bifidobacterium breve type strain ( Bifidobacterium breve (KCTC3220 T ) type stain) according to the present invention, showing the recovery of cell viability inhibited by NAMPTi. The results show that it has an impact.
- Figure 4 shows the results of increase in NAD + and total NAD content by Bifidobacterium breve ID-A11 according to the present invention.
- Figure 5 compares Bifidobacterium breve ID-A11 and Bifidobacterium breve (KCTC3220T) type stain according to the present invention, showing the contents of NAD + and total NAD inhibited by NAMPTi This shows the recovery results.
- Figure 6 shows the results of analyzing the intracellular ATP content by comparing Bifidobacterium breve ID-A11 and Bifidobacterium breve type strain ( Bifidobacterium breve (KCTC3220T) type stain) according to the present invention.
- Figure 7 shows the results confirming the increase in NAD + content in the body and the synergistic effect of combined administration when Bifidobacterium breve ID-A11 according to the present invention is administered alone or in combination with NR.
- Figure 8 shows the results of a forced swim test (FST) in the group administered Bifidobacterium breve ID-A11 alone or in combination with NR according to the present invention.
- FST forced swim test
- Figure 9 shows the results confirming the increase in soleus muscle weight following administration of Bifidobacterium breve ID-A11 alone or in combination with NR according to the present invention.
- Figure 10 shows the results confirming the increase in the expression of NAD + and mitochondrial biosynthetic gene SIRT1 following administration of Bifidobacterium breve ID-A11 alone or in combination with NR according to the present invention.
- Figure 11 shows the results confirming the increase in expression of NAD + and mitochondrial biosynthetic gene NRF1 following administration of Bifidobacterium breve ID-A11 alone or in combination with NR according to the present invention.
- the inventors of the present application found that the salvage pathway does not operate smoothly due to a decrease in NAMPT (nicotinamide phosphoribosyltransferase) enzyme in the body, ultimately leading to a decrease in NAD + and accumulation of NAM (nicotinamide), but the novel Bifi gambling of the present invention.
- NAMPT nicotinamide phosphoribosyltransferase
- NAM nicotinamide
- NAD + can be promoted through the novel Bifidobacterium breve strain of the present invention.
- Total NAD refers to the total of NAD + and NADH, and the total NAD level can be increased by increasing NAD + according to the present invention.
- novel Bifidobacterium breve strain of the present invention can improve exercise performance or muscle endurance, increase muscle mass, and have an effective effect on improving muscle diseases, such as sarcopenia. did.
- the present invention relates to the Bifidobacterium breve ID-A11 strain or a culture thereof with accession number KCTC 15219BP.
- the Bifidobacterium breve ID-A11 strain according to the present invention was deposited with the Korea Research Institute of Bioscience and Biotechnology on December 5, 2022 under the deposit number KCTC 15219BP.
- the strain has the ability to convert NAM, a NAD precursor, to NA.
- the NA produced is NAD + and It can increase the level of total NAD, including this.
- NAD + is a key molecule that regulates activities between the nucleus and mitochondria, enabling signal transmission, and plays a central role in obtaining energy from nutrients in a form usable by cells. Additionally, NAD + activates a protein called SIRT1, which is known to promote healthy metabolism throughout the body.
- the efficiency may be reduced because ATP is consumed to actively pass NAD + outside the cell through the cell membrane or mitochondrial membrane.
- the Bifidobacterium breve strain of the present invention has the advantage of not requiring energy for intracellular penetration because it can convert NAM, a component in the body, into NA.
- NAD + is converted into toxins such as L-tryptophan (Trp: L-tryptophan), nicotinic acid (NA), and nicotinamide (NAM). It is synthesized from a variety of dietary precursors. In particular, the salvage pathway is the most important pathway for producing and maintaining NAD + in mammals.
- Trp L-tryptophan
- NA nicotinic acid
- NAM nicotinamide
- NMN (nicotinamide mononucleotide) is generated from NAM by NAMPT (nicotinamide phosphoribosyltransferase), and NMN is converted to NAD + by NMNAT (nicotinamide mononucleotide adenylyltransferase).
- the salvage pathway does not operate smoothly due to inhibition or reduction of NAMPT (nicotinamide phosphoribosyltransferase) enzyme in the body, ultimately leading to accumulation of NAM (nicotinamide) and reduction of NAD + , NAM ( nicotinamide) conversion ability, it was confirmed that NAD + and total NAD levels could be increased by converting accumulated NAM into NA and activating the Preiss-Handler pathway.
- NAMPT nicotinamide phosphoribosyltransferase
- culture may mean culturing the strain in a culture medium or culture medium.
- the culture may contain the strain, contain lysate of the strain, or be a cell-free supernatant that does not contain the strain.
- the culture may be liquid or solid in formulation, but is not limited thereto.
- the medium may be selected from known liquid media or solid media, for example, MRS liquid medium, GAM liquid medium, MRS agar medium, GAM agar medium, and BL agar medium, but is not limited thereto.
- the shredded material refers to the form destroyed by strain enzyme treatment, homogenization, or ultrasonic treatment.
- Various forms of the culture may be included, such as concentrate, dried matter, or extract of the culture.
- the extract can be extracted using a known extraction solvent, such as water or an organic solvent, such as water, a lower alcohol having 1 to 4 carbon atoms, hexane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be extracted using .
- a known extraction solvent such as water or an organic solvent, such as water, a lower alcohol having 1 to 4 carbon atoms, hexane, chloroform, ethyl acetate, or a mixed solvent thereof. It can be extracted using .
- the strain can be transported in a pharmaceutically acceptable carrier such as, for example, colloidal suspension, powder, saline solution, lipids, liposomes, microspheres, or nano-spherical particles. They may form complexes or associate with delivery vehicles and may be used in the art as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrimers, saponins, adsorption enhancers or fatty acids. It can be transported in vivo using known delivery systems.
- a pharmaceutically acceptable carrier such as, for example, colloidal suspension, powder, saline solution, lipids, liposomes, microspheres, or nano-spherical particles. They may form complexes or associate with delivery vehicles and may be used in the art as lipids, liposomes, microparticles, gold, nanoparticles, polymers, condensation agents, polysaccharides, polyamino acids, dendrim
- the present invention provides a composition for enhancing NAD + and/or total NAD in the body comprising the Bifidobacterium breve strain or a culture thereof. Additionally, the present invention provides a method for enhancing NAD + and/or total NAD in the body, comprising administering the Bifidobacterium breve strain or culture thereof to an individual. Moreover, the present invention provides the use of the Bifidobacterium breve strain or its culture for producing a composition for enhancing NAD + and/or total NAD in the body.
- the composition for enhancing NAD + and/or total NAD in the body may be a pharmaceutical composition. Based on this, the present invention provides a pharmaceutical composition for enhancing NAD + and/or total NAD in the body containing the Bifidobacterium breve strain or a culture thereof.
- the strain has the ability to convert NAM, a NAD precursor, to NA.
- the NA produced is NAD + and It can increase the level of total NAD, including this.
- the present invention provides a pharmaceutical for enhancing NAD + and/or total NAD in the body for use in combination with Nicotinamide Riboside, comprising the Bifidobacterium breve strain or culture thereof. It relates to composition.
- the present invention relates to a composition
- a composition comprising a Bifidobacterium breve strain or a culture thereof and nicotinamide riboside.
- the composition may be a pharmaceutical composition or a food composition, and the food composition may include a health functional food composition, a general food composition, and a functional food composition.
- the Bifidobacterium breve strain or culture thereof and Nicotinamide Riboside preferably have complementary activities, so that they do not adversely affect each other.
- compositions may be (1) co-formulated in a complex formulation and administered or delivered simultaneously; (2) Can be administered or delivered simultaneously or sequentially as separate dosage forms.
- the Bifidobacterium breve strain or its culture and nicotinamide riboside may be present in the same composition.
- the formulation may be, for example, but is not limited to a dried powder composition, solution, or suspension.
- the Bifidobacterium breve strain or its culture and nicotinamide riboside can be administered simultaneously or sequentially. They are generally separated from each other and may be administered simultaneously or sequentially. When administered sequentially, it can be administered in two or more doses. When administered sequentially, one of the Bifidobacterium breve strain or culture and nicotinamide riboside may be administered followed by the other, or alternately with an interval between the two administrations.
- the present invention relates to a pharmaceutical composition for enhancing exercise performance or muscular endurance containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a pharmaceutical composition for enhancing exercise performance or muscular endurance, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside. .
- “Exercise performance” is closely related to the improvement of athletes’ performance and records, and can be improved by improving cardiorespiratory function, promoting energy metabolism, recovering from fatigue, and increasing muscle strength. In other words, exercise performance can be improved by quickly recovering fatigue accumulated during long-term training and increasing endurance during exercise.
- Muscular endurance refers to the ability of muscles to continue working for long periods of time without fatigue. It is the most basic ability that constitutes whole-body endurance, and is an ability that indicates how long or how many times a muscle can repeat contraction and relaxation with a given weight, and can be trained through strength training.
- the present invention relates to a pharmaceutical composition for preventing or treating muscle disease comprising the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a pharmaceutical composition for the prevention or treatment of muscle disease, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside.
- Muscle is the most abundant tissue in the human body, and securing an appropriate amount of muscle is essential to maintain the functional capacity of the human body and prevent metabolic diseases.
- the muscle disease is a progressive disease characterized by loss of walking ability, weakened respiratory muscle, weakened heart function, etc. due to gradual decrease in muscle strength, and may be, for example, muscle degeneration, sarcopenia, or muscular dystrophy.
- the sarcopenia may be senile sarcopenia.
- muscle includes tendons, muscles, and tendons
- muscle function refers to the ability to exert force through muscle contraction. Muscles can exert maximum contractile force to overcome resistance. It includes strength, which is the ability, muscular endurance, which is the ability to express how long or how many times a muscle can repeat contraction and relaxation with a given weight, and quickness, which is the ability to exert strong force in a short period of time.
- prevention or treatment of muscle disease includes suppressing the occurrence of muscle degeneration, sarcopenia or muscular dystrophy, alleviating the occurrence of muscle degeneration, sarcopenia or muscular dystrophy, preventing recurrence, and alleviating symptoms.
- the present invention relates to a pharmaceutical composition for muscle strengthening containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a pharmaceutical composition for muscle strengthening, which contains a Bifidobacterium breve strain or a culture thereof and is used in combination with nicotinamide riboside.
- the muscle strengthening refers to the effect of increasing muscle strength and/or size, and does not limit the type of muscle.
- the muscle strengthening includes increasing muscle mass and may include increasing the number of muscle fibers and/or muscle cross-sectional area.
- the present invention also relates to a pharmaceutical composition for preventing or treating aging-related diseases, comprising the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a pharmaceutical composition for preventing or treating age-related diseases, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside. .
- the aging-related disease may be a neurodegenerative disease or a cognitive dysfunction disease.
- the neurodegenerative disease may be, for example, dementia, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
- the cognitive dysfunction disease may be dementia related to perception, memory, language understanding, etc.
- SIRT1 mitochondrial biosynthesis gene
- composition of the present invention may be effective in preventing or treating Parkinson's disease.
- the pharmaceutical composition is prepared in unit dosage form by formulating using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person skilled in the art to which the present invention pertains. It can be manufactured by placing it in a capacity container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule, or gel (e.g., hydrogel), and may additionally contain a dispersant or stabilizer. there is.
- a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily performed by a person skilled in the art to which the present invention pertains. It can be manufactured by placing it in a capacity container. At this time, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or may be in the form of an extract, powder, granule, tablet, capsule, or gel
- Pharmaceutically acceptable carriers include those commonly used in preparations: lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyro. It may include, but is not limited to, rhodium, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition, in addition to the above ingredients, lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. may be additionally included.
- the pharmaceutical composition can be administered orally or parenterally and can be used in the form of a general pharmaceutical preparation. That is, the pharmaceutical composition of the present invention can be administered in various oral and parenteral dosage forms during actual clinical administration.
- diluents such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants, or It is prepared using excipients.
- Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. do.
- Liquid preparations for oral administration include suspensions, oral solutions, emulsions, and syrups.
- simple diluents such as water and liquid paraffin
- various excipients such as wetting agents, sweeteners, fragrances, and preservatives may be included.
- Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories.
- Non-aqueous solvents and suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate.
- injectable ester such as ethyl oleate.
- Withepsol, Macrogol, Tween 61, cacao, laurel, glycerol, gelatin, etc. can be used as a base for suppositories.
- Withepsol, Macrogol, Tween 61, cacao, laurel, glycerol, gelatin, etc. can be used as a base for suppositories.
- the concentration of the active ingredient included in the composition can be determined considering the purpose of treatment, patient condition, required period, etc., and is not limited to a specific concentration range.
- the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
- 'pharmacologically effective amount' refers to an amount sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is determined by the type, severity of the patient's disease, the activity of the drug, and the drug. It can be determined based on factors including sensitivity, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical field.
- the pharmaceutical composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered simultaneously, separately, or sequentially with conventional therapeutic agents, and may be administered singly or multiple times.
- the effective dose may vary depending on the patient's age, gender, condition, weight, absorption of the active ingredient in the body, inactivation rate, excretion rate, type of disease, and concomitant drug, and may vary depending on the route of administration, severity, gender, weight, age, etc. It can increase or decrease.
- the composition for enhancing NAD + and/or total NAD in the body may be a food composition.
- the present invention provides a food composition for enhancing NAD + and/or total NAD in the body containing the Bifidobacterium breve strain or a culture thereof.
- the strain has the ability to convert NAM, a NAD precursor, to NA.
- the NA produced is NAD + and It can increase the level of total NAD, including this.
- the present invention also relates to a food composition for enhancing NAD + in the body, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside.
- the present invention also relates to a food composition for enhancing total NAD in the body, which includes the Bifidobacterium breve strain or a culture thereof and is for use in combination with nicotinamide riboside.
- the present invention also relates to a food composition for enhancing exercise performance or muscular endurance containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a food composition for enhancing exercise performance or muscular endurance, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside. .
- the present invention also relates to a food composition for preventing or improving muscle disease containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a food composition for preventing or treating muscle disease, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside.
- the present invention also relates to a food composition for muscle strengthening containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a food composition for muscle strengthening containing the Bifidobacterium breve strain or a culture thereof and for use in combination with nicotinamide riboside.
- the present invention also relates to a food composition for preventing or improving aging-related diseases containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a food composition for preventing or improving aging-related diseases, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside. .
- the present invention also relates to a food composition for preventing or improving aging containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to a food composition for preventing or improving aging, comprising the Bifidobacterium breve strain or a culture thereof, and for use in combination with nicotinamide riboside.
- Age-related diseases may be neurodegenerative diseases or cognitive dysfunction diseases.
- the neurodegenerative disease may be, for example, dementia, Alzheimer's disease, Huntington's disease, or Parkinson's disease.
- the cognitive dysfunction disease may be dementia related to perception, memory, language understanding, etc.
- the present invention also relates to an anti-aging composition containing the Bifidobacterium breve strain or a culture thereof.
- the present invention also relates to an anti-aging composition comprising the Bifidobacterium breve strain or a culture thereof and for use in combination with nicotinamide riboside.
- the anti-aging composition may be a food composition for preventing or improving aging.
- the Bifidobacterium breve ID-A11 strain or culture thereof of the present invention can prevent or delay aging mediated by NAD by increasing the amount of NAD + and total NAD in the body, and mitochondrial biosynthesis genes By increasing the expression of (SIRT1), it can ultimately delay aging or signs of aging in the body, including muscles, skin, etc.
- Foods according to the present invention include health functional foods, general foods, or functional foods.
- the food may be a health functional food, general food, or functional food.
- health functional food or functional food refers to food with high medical or medical effect that has been processed to efficiently exhibit bioregulatory functions in addition to nutritional supply.
- Health functional food or functional food refers to tablets, capsules, etc. to obtain useful effects. It can be manufactured in various forms such as powder, granule, liquid, and pill.
- the above health functional foods refer to foods manufactured and processed using raw materials or ingredients with functionality useful to the human body in accordance with the Act on Health Functional Foods, and provide health benefits such as regulating nutrients for the structure and function of the human body or physiological effects. It means ingestion for the purpose of obtaining useful effects.
- the above health functional food may contain common food additives, and its suitability as a food additive is determined by the specifications and standards for the relevant item in accordance with the general provisions of the Food Additive Code and General Test Methods approved by the Food and Drug Administration, unless otherwise specified. Judgment is made according to standards.
- the above health functional foods include beverages, meat, chocolate, foods, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, or health supplements, without limitation, for their purpose of use (prevention or improvement). It can be processed accordingly.
- the food composition can be added as is or used together with other foods or food ingredients, and can be used appropriately according to conventional methods.
- the amount of active ingredient can be appropriately used depending on the purpose of use (prevention or improvement).
- foods to which the food composition can be added include meat, sausages, bread, chocolate, candies, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea drinks, These include alcoholic beverages and vitamin complexes, and can include all health foods in the conventional sense.
- the food composition can be manufactured into a food, especially a functional food.
- the food composition of the present invention includes ingredients commonly added during food production and may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
- ingredients commonly added during food production may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings.
- natural carbohydrates or flavoring agents may be included as additional ingredients in addition to the active ingredient.
- the natural carbohydrates include monosaccharides (e.g., glucose, fructose, etc.), disaccharides (e.g., maltose, sucrose, etc.), oligosaccharides, polysaccharides (e.g., dextrins, cyclodextrins, etc.), or sugar alcohols (e.g., , xylitol, sorbitol, erythritol, etc.) are preferred.
- the flavoring agent may be a natural flavoring agent (e.g., thaumatin, stevia extract, etc.) or a synthetic flavoring agent (e.g., saccharin, aspartame, etc.).
- the concentration of the strain in the composition may be, for example, 10 5 CFU/mL to 10 11 CFU/mL, and specifically 10 10 CFU/mL, but is not limited thereto.
- the concentration of the strain is, for example, 10 5 CFU/mL or more, specifically It may be 10 5 CFU/mL to 10 11 CFU/mL, and more specifically, 10 10 CFU/mL, but is not limited thereto.
- the concentration of nicotinamide riboside in the composition of the present invention may be, for example, 100 mg/kg/day to 60,000 mg/day, specifically 300 mg/day to 18,000 mg/day, based on a body weight of 60 kg of an adult, but is limited thereto. It doesn't work. Excellent effects may occur when the Bifidobacterium breve strain or its culture is used together within the concentration range of nicotinamide riboside.
- the present invention provides a probiotic preparation containing Bifidobacterium breve ID-A11 strain or a culture thereof.
- probiotics in the present invention refers to live bacteria, that is, microorganisms that can survive and stay in the gastrointestinal tract when ingested by humans or animals, and are microbial preparations that are effective in preventing or treating specific pathological conditions.
- probiotics are effective in treating and improving various symptoms caused by abnormal fermentation of intestinal flora. When administered to humans and animals, they crowd and settle on the walls of the digestive tract and prevent harmful microorganisms from settling, causing lactic acid. It inhibits the growth of harmful microorganisms by lowering the intestinal pH.
- the strain culture medium contains various antibacterial organic acids and non-proteinaceous antibacterial substances produced by the strain, so when included as an active ingredient in a probiotic composition, it can exhibit the same effect as a composition containing the strain.
- the probiotic preparation of the present invention is suitable for ingestion with other lactic acid bacteria, suppresses the growth of harmful microorganisms upon ingestion, and may additionally contain other types of known microorganisms that have the activity of improving the balance of intestinal flora. You can.
- the probiotic preparation of the present invention can be prepared and administered in various formulations and methods according to methods known in the art.
- the strain of the present invention, its culture, a concentrate of the culture, or a dried product thereof can be mixed with a carrier commonly used in the pharmaceutical field to produce powders, liquids and solutions, tablets, and capsules. It can be manufactured and administered in the form of a capsule, syrup, suspension, or granule.
- the carrier may include, for example, a binder, a lubricant, a disintegrant, an excipient, a solubilizer, a dispersant, a stabilizer, a suspending agent, a coloring agent, and a flavoring agent, but is not limited thereto.
- the administered dose can be appropriately selected depending on the absorption rate of the active ingredient in the body, the inactivation rate, the excretion rate, the age, gender, species, condition, and severity of the disease of the recipient.
- composition according to the present invention may be a cosmetic composition.
- the present invention relates to an anti-aging cosmetic composition containing Bifidobacterium breve ID-A11 strain or a culture thereof.
- the ID-A11 strain of the present invention or its culture can delay aging or signs of aging by increasing the expression of the mitochondrial biogenesis gene (SIRT1) in the body.
- SIRT1 mitochondrial biogenesis gene
- the cosmetic composition can be prepared in a general emulsified formulation or solubilized formulation.
- the cosmetic composition can be appropriately formulated depending on the area to which it is applied.
- lotion such as softening lotion or nourishing lotion
- Emulsions such as facial lotion and body lotion
- Creams such as nutritional cream, moisture cream, eye cream, etc.; essence; cosmetic ointment; spray; gel; pack; sunscreen; makeup base; Foundation, such as liquid type, solid type, or spray type; powder
- Foundation such as liquid type, solid type, or spray type
- powder It may be formulated in oil, etc., but is not limited thereto.
- the strain was isolated from infant feces and named ID-A11.
- 16S rRNA sequence analysis was requested from Macrogen (Seoul, Korea). Specifically, 16S rRNA sequence analysis was performed, and PCR was performed on the 16S rRNA gene using primers 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (3'-TACGGYTACCTTGTTACGACTT-5'). The results obtained from the base sequence analysis were also compared for homology using information registered in the database of the NCBI (National Center for Biotechnology Information).
- ID-A11 was confirmed to be Bifidobacterium breve as it showed 99% similarity to Bifidobacterium breve DSM 20213.
- Bifidobacterium breve ID-A11 strain was deposited with the Korea Research Institute of Bioscience and Biotechnology on December 5, 2022, and the deposit number KCTC 15219BP was obtained.
- ID-A11 Bifidobacterium breve ID-A11
- KCTC3220 T Bifidobacterium breve type strain
- WST analysis was used to measure cell viability.
- 2.5 NAMPTi was added at a concentration of 0.2 nM, and ID-A11 and TS were added at a concentration of 2.5
- color development by live cells was induced using WST reagent (DoZEN, EZ-3000), and absorbance was measured at OD 450nm using a microplate reader (Bio-TEK, Synergy H4).
- DoZEN DoZEN, EZ-3000
- NAMPTi treatment resulted in a decrease in cell viability of about 20% to 79.6% compared to the control (100%).
- Reduced cell viability was recovered by B. breve , showing cell viability of approximately 94.9% in ID-A11 and approximately 84% in TS ( Figure 3).
- Bifidobacterium breve has an effective effect on the recovery of cell viability inhibited by NAMPTi, and its effect is in ID-A11 according to the present invention. It was confirmed that it was higher.
- NAD NAD
- the NAD + content was confirmed to be approximately 263% compared to the control (100%).
- the total NAD content was also considered considering the amount that would have been reduced to NADH according to cell metabolism, and the total NAD content also showed a similar tendency to that of NAD + (Figure 4).
- NAD NAD
- a NAD (NADH) analysis kit Biomax, BM-NDA-100
- 2.5 NAMPTi was added at a concentration of 0.2 nM
- ID-A11 and TS were added at a concentration of 2.5 HCT-15 recovered after 24 hours of additional culture was treated with NAD extraction buffer to induce color development according to the total intracellular NAD and NADH content, and OD was measured using a microplate reader (Bio-TEK, Synergy H4). Absorbance was measured at 450 nm .
- NAD+ content in HCT-15 following NAMPTi treatment decreased by about 72% to 28.0% compared to the control group (100%).
- Reduced NAD+ content is associated with Bifidobacterium breve TS showed a NAD+ content of about 93%, and ID-A11 showed a NAD+ content exceeding the control group at about 125%.
- NAD + the total NAD content was also considered considering the amount that would have been reduced to NADH according to cell metabolism. Compared to TS, the total amount of NAD in ID-A11 was 133.2% compared to TS (100%), producing 33.2% more total NAD.
- Bifidobacterium breve It was confirmed that it has an effective effect on promoting NAD + and species NAD inhibited by NAMPTi, and that the effect is significantly higher in Bifidobacterium breve ID-A11.
- An ATP assay kit (abcam, ab83355) was used to analyze intracellular ATP content. 2.5 Bacteria were added so that ID-A11 and TS were 12.5 HCT-15 recovered after 48 hours of additional culture was treated with ATP assay buffer to induce color development according to intracellular ATP content, and absorbance was measured at OD 570 nm using a microplate reader (Bio-TEK, Synergy H4). .
- NAD NAD
- NR Neurotinamide riboside chloride
- HCT-15 was treated with NAD extraction buffer to induce color development according to the intracellular total NAD, NADH (total NAD, NADH) content, and a microplate reader (Bio-TEK, Synergy H4) ) was used to measure the absorbance at OD450nm.
- the FST of the animals judged to be healthy was measured and ranked, and the average FST measurement value of each group was evenly distributed as in the composition of the test groups. It was distributed randomly.
- Each group was normal (G1), NR 2.16 mg/mice administered group (G2), ID-A11 7.2 x 10 6 CFU/mice administered group (G3), ID-A11 7.2 x 10 7 CFU/mice administered group (G4), NR. 2.16 mg/mice + ID-A11 7.2
- the normal group (G1) was administered saline. 0.35 ml was administered per subject, and the test groups also administered the test substance suspended in the same volume of 0.35 ml saline.
- Saline solution was administered to the Normal group, and test substances in the experimental group were prepared according to the administration concentration of each group and administered orally 7 times a week, once a day, for 6 weeks (total of 42 times).
- Forced swim test (FST) was performed at weeks 0 and 6, and the remaining evaluation items were performed on animals that had completed 6 weeks of drug administration, were fasted 18 hours before necropsy, were anesthetized by inhalation with isoflurane, and blood was collected from the posterior vena cava. was obtained.
- the collected blood was injected into an SST tube containing clot activator, left at room temperature for about 30 minutes to coagulate, and then centrifuged at 3000 rpm for 10 minutes to separate serum. Both hindlimb muscles were collected from animals after blood collection was completed. Serum and collected muscles were stored in a deep freezer.
- FST was performed at weeks 0 and 6. However, swimming practice was conducted for about 5 minutes a day starting 2 days before the FST. After filling the tank with water so that the animal's tail did not touch the bottom, the animal was allowed to swim by attaching a weight of 5% of its body weight to the tail. The swimming time of the animal swimming on the surface of the water was measured, and if the animal did not rise to the surface, swimming was stopped and the time until that point was recorded.
- the collected muscles were stored in a deep freezer and analyzed for mitochondrial biosynthetic genes (SIRT1, NRF1) using qPCR.
- NRF1 was observed in all treatment groups (G3-G6) containing ID-A11 compared to the normal group (G1). An increase in NRF1 was observed in G5 compared to G2 and G3. An increase in NRF1 was observed in G6 compared to G2 and G4 ( Figure 11).
- Salvage pathway does not operate smoothly due to a decrease in NAMPT (nicotinamide phosphoribosyltransferase) enzyme in the body, ultimately reducing NAD + and accumulating NAM (nicotinamide).
- NAMPT nicotinamide phosphoribosyltransferase
- the NAM conversion ability of the Bifidobacterium breve strain selected through the present invention Through this, the accumulated NAM can be converted to NA and the Preiss-Handler pathway can be activated, ultimately increasing NAD + and total NAD levels.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne une nouvelle souche de Bifidobacterium breve, une culture de celle-ci, et une composition la comprenant. Plus particulièrement, une souche de Bifidobacterium breve nouvellement isolée et une culture de celle-ci peuvent permettre d'obtenir des effets anti-âge et une amélioration de la fonctionnalité musculaire grâce à une augmentation in vivo des niveaux de NAD et de l'activité de SIRT1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20220183271 | 2022-12-23 | ||
| KR10-2022-0183271 | 2022-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2024136604A1 true WO2024136604A1 (fr) | 2024-06-27 |
Family
ID=91589665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2023/021477 WO2024136604A1 (fr) | 2022-12-23 | 2023-12-22 | Souche de bifidobacterium breve et composition pour augmenter le nad+ et le nad total la comprenant |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2024136604A1 (fr) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101611830B1 (ko) * | 2015-06-08 | 2016-04-27 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 비피도박테리움 브레베 cbt br3 균주 및 이를 포함하는 조성물 |
| KR20170078367A (ko) * | 2015-12-29 | 2017-07-07 | 서울대학교산학협력단 | 비피도박테리움 브레베 ldtm8001(kctc 18423p) 및 비피도박테리움 브레베 ldtm 8002(kctc 18424p)를 조합 배양하여 리놀레산을 공액리놀레산으로 전환하는 방법 |
| EP3704958A1 (fr) * | 2017-10-31 | 2020-09-09 | Morinaga Milk Industry Co., Ltd. | Composition pour augmentation de la masse musculaire |
| KR20210005717A (ko) * | 2018-05-01 | 2021-01-14 | 시에이치알. 한센 에이/에스 | 프로바이오틱 비피도박테리움 브레베 균주 및 상기 균주를 포함하는 조성물 |
-
2023
- 2023-12-22 WO PCT/KR2023/021477 patent/WO2024136604A1/fr unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101611830B1 (ko) * | 2015-06-08 | 2016-04-27 | 주식회사 쎌바이오텍 | 비만 및 비만으로 야기된 대사성 질환의 예방 또는 치료를 위한 비피도박테리움 브레베 cbt br3 균주 및 이를 포함하는 조성물 |
| KR20170078367A (ko) * | 2015-12-29 | 2017-07-07 | 서울대학교산학협력단 | 비피도박테리움 브레베 ldtm8001(kctc 18423p) 및 비피도박테리움 브레베 ldtm 8002(kctc 18424p)를 조합 배양하여 리놀레산을 공액리놀레산으로 전환하는 방법 |
| EP3704958A1 (fr) * | 2017-10-31 | 2020-09-09 | Morinaga Milk Industry Co., Ltd. | Composition pour augmentation de la masse musculaire |
| KR20210005717A (ko) * | 2018-05-01 | 2021-01-14 | 시에이치알. 한센 에이/에스 | 프로바이오틱 비피도박테리움 브레베 균주 및 상기 균주를 포함하는 조성물 |
Non-Patent Citations (1)
| Title |
|---|
| KATSYUBA ELENA, AUWERX JOHAN: "Modulating NAD+ metabolism, from bench to bedside", THE EMBO JOURNAL / EUROPEAN MOLECULAR BIOLOGY ORGANIZATION, IRL PRESS, OXFORD, vol. 36, no. 18, 15 September 2017 (2017-09-15), Oxford , pages 2670 - 2683, XP093187568, ISSN: 0261-4189, DOI: 10.15252/embj.201797135 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018012834A1 (fr) | Souche d'akkermansia muciniphila présentant un effet de prévention ou de traitement de maladies dégénératives du cerveau ou de maladies métaboliques et utilisation correspondante | |
| WO2019151843A1 (fr) | Souche de lactobacillus plantarum kbl396 et son utilisation | |
| WO2019199094A1 (fr) | Nouvelle souche de bifidobacterium longum ou de lactobacillus rhamnosus ayant pour effet de prévenir ou de traiter l'obésité, et utilisation correspondante | |
| WO2018062914A1 (fr) | Nouveau lactobacillus sakei et composition le comprenant | |
| WO2020130471A1 (fr) | Nouveau lactobacillus ayant un effet de réduction du poids corporel ou de la graisse corporelle et son utilisation | |
| WO2023055188A1 (fr) | Nouveaux probiotiques et utilisation associée | |
| WO2017047962A1 (fr) | Nouveau lactobacillus et composition pour prévenir, atténuer ou traiter des maladies cérébrales dégénératives ou des troubles de la fonction cognitive | |
| WO2020076043A1 (fr) | Bactéries du microbiote intestinal présentant un effet prophylactique ou thérapeutique contre la dépression, et utilisation correspondante | |
| WO2020040382A1 (fr) | Nouveau composé de magnésium-sérinate et son utilisation | |
| WO2014196775A1 (fr) | Souche de lactobacillus brevis g-101 et son utilisation | |
| WO2020071660A1 (fr) | Composition anti-âge contenant comme principe actif une souche d'akkermansia muciniphila ou une culture de cette dernière | |
| WO2024136604A1 (fr) | Souche de bifidobacterium breve et composition pour augmenter le nad+ et le nad total la comprenant | |
| WO2020045972A1 (fr) | Souche de lactobacillus fermentum mg4231 ou de lactobacillus fermentum mg4244 dérivé du corps humain, ayant une activité anti-obésité, et composition la comprenant | |
| WO2017023099A1 (fr) | Composition pour augmenter les bactéries lactiques intestinales et méthode de production de bactéries lactiques l'utilisant | |
| WO2022265431A1 (fr) | Utilisation d'une souche de lactobacillus fermentum et de lymphocytes t régulateurs en polythérapie pour la prévention et le traitement d'une maladie métabolique | |
| WO2023068857A1 (fr) | Nouvelle souche bactérienne possédant une activité anticancéreuse et composition permettant de soulager, de prévenir ou de traiter le cancer l'utilisant | |
| WO2015167240A1 (fr) | Composition contenant un extrait de scutellaria alpina | |
| WO2016093613A2 (fr) | Composition pour la prévention ou le traitement d'une perte de poids anormale, contenant un extrait de pelure de mandarine satsuma | |
| WO2022039514A1 (fr) | Composition pour le traitement de maladies cérébrales comprenant lactobacillus sakei ou des vésicules extracellulaires dérivées de celui-ci en tant que principe actif | |
| WO2022255744A1 (fr) | Vésicule issue de lactobacillus plantarum et son utilisation | |
| WO2023058801A1 (fr) | Composition pour soulager, prévenir ou traiter un trouble intestinal, comprenant une souche de lactobacillus acidophilus kbl402 ou kbl409 | |
| WO2021080298A1 (fr) | Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière | |
| WO2015152653A1 (fr) | Composition comprenant un extrait de feuilles de génépi blanc | |
| WO2023153903A1 (fr) | Composition pour la prévention ou le traitement de la stéatose hépatique, comprenant, en tant que principe actif, enterococcus faecalis, sa solution de culture ou ses cellules mortes | |
| WO2022035220A1 (fr) | Composition pour prévenir, améliorer ou traiter des maladies musculaires liées à une faiblesse musculaire comprenant un extrait de fleur de châtaigne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23907887 Country of ref document: EP Kind code of ref document: A1 |